2 months ago
12
Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. ("Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conference in the month of February:
- Oppenheimer 35th Annual Healthcare Life Sciences Conference, Virtual, February 11-12, 2025
Sijmen de Vries, Chief Executive Officer and Anurag Relan, Chief Medical Officer, will present on Wednesday, February 12 at 08:40 ET/14:40 CET. A live webcast and replay of the presentation will be available in the "Upcoming Events” and "News” sections of Pharming's website.
For more information about this conference, or to schedule a one-to-one meeting with Pharming's management team, please contact Pharming's Investor Relations team at [email protected] or your Oppenheimer representative.
About Pharming Group N.V.
Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
FTI Consulting, London, United Kingdom
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
Attachment
